Posted 03 January, 2023
SWK Holdings Corp appointed Jody Staggs as new CEO
Nasdaq:SWKH appointed new Chief Executive Officer Jody Staggs in a 8-K filed on 03 January, 2023.
On December 12, 2022, the board of directors (the "Board") of SWK Holdings Corporation (the "Company"), appointed Jody Staggs, the Company's current President and Interim Chief Executive Officer, as Chief Executive Officer, effective January 1, 2023.
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SWK Holdings Corp
Technology • Software
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.Market Cap
$204M
View Company Details
$204M
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer On December 12, 2022, the board of directors (the "Board") of SWK Holdings Corporation (the "Company"), appointed Jody Staggs, the Company's current President and Interim Chief Executive Officer, as Chief Executive Officer, effective January 1, 2023. In connection with Mr. Staggs' appointment as Chief Executive Officer, on January 2, 2023, the Company entered into an employment agreement with Mr. Staggs (the "Employment Agreement"), with an effective date of January 1, 2023 (the "Effective Date"). Pursuant to the Employment Agreement, Mr. Staggs' (i) initial annual base salary will be $400,000 (the "Base Salary"), (ii) will be eligible for an annual bonus with a target opportunity of 175% of Base Salary (the "Annual Bonus") and (iii) will be eligible for annual equity incentive awards in such form, in such amounts and on such terms as determined by the Compensation Committee of the Board, in its discretion; provided, however, that Mr. Staggs' 2023 annual equity award will have a grant date fair value of approximately $600,000. The Employment Agreement also provides that Mr. Staggs shall be entitled to participate in the employee benefit plans and programs maintained by the Company for similarly situated employees. The Employment Agreement provides that, if Mr. Staggs' employment with the Company ceases due to a termination by the Company without Cause or resignation by him with Good Reason (each as defined in the Employment Agreement), then he will receive: (i) continued payment of his Base Salary for a period of 12 months following the date of his termination of employment (or 18 months, if such termination occurs within one year following a Change in Control (as defined in the Employment Agreement), (ii) to the extent an Annual Bonus has been earned but not paid with respect to the fiscal year ended immediately prior to the cessation of Mr. Staggs' employment, payment of such Annual Bonus; (iii) waiver or reimbursement of the cost of COBRA coverage for Mr. Staggs and his covered family members for 12 months following such termination of employment (or 18 months, if such termination occurs within one year following a Change in Control), (iv) a pro rata Annual Bonus for the fiscal year in which Mr. Staggs' termination of employment occurs based on actual results for such year; and (v) Mr. Staggs' outstanding equity awards will be treated in accordance with the Company's applicable equity plan and award agreements, unless a more generous treatment is approved by the Board or the Compensation Committee. Any severance benefit payable under the Employment Agreement will be subject to Mr. Staggs' timely execution and non-revocation of a release of claims. Mr. Staggs will also be bound by confidentiality, intellectual property assignment and restrictive covenants (including an agreement not to compete with the Company or its affiliates, and not to solicit the employees and customers of the Company and its affiliates, during his employment and for 12 months thereafter). The above description of the Employment Agreement is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed hereto as Exhibit 10.1 and incorporated herein by reference. No family relationship exists between Mr. Staggs and any of the Company's directors or executive officers. There are no arrangements or understandings between Mr. Staggs and any other person pursuant to which Mr. Staggs was selected as an officer of the Company, nor are there any transactions to which the Company is or was a participant and in which Mr. Staggs had or will have a direct or indirect material interest subject to disclosure under Item 404(a) of Regulation S-K.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.